Warning signs were always there for Novartis’s Avexis deal
High-profile departures at Avexis raise more questions about Novartis’s acquisition, but there were plenty of red flags before the deal was sealed.
Novartis’s Narasimhan faces his first big test
Revelations of data manipulation might not be fatal, but they will hurt the chief exec’s attempted rebranding of Novartis as a more ethical pharma company.
Biogen leads the way in renewed amyotrophic lateral sclerosis push
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
Threats to Spinraza are mounting, but Biogen still has cards to play
Competition is looming from Novartis and Roche but the latest results from Spinraza show that Biogen still has a strong case to make for the SMA therapy.
Merck and the pitfalls of biopharma success
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
Big hitters eye Sjögren’s syndrome white space
Orencia’s late-stage failure in Sjögren’s has dashed hopes of a therapy soon, but the mid-stage pipeline is crowded, with Novartis, Glaxosmithkline and Galapagos all…
Takeda casts doubt on the remaining approach to amyloidosis
After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.
Reality bites for Macrogenics
Hopes are fading for margetuximab in breast cancer, which looks unlikely to show an overall survival benefit in the Sophia study.
Price fixing case caps a terrible week for generics
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.